OXB is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, while retaining proprietary drug candidates. OXB will also receive royalties on commercial products developed with its LentiVector® platform. The first half of 2018 delivered significant growth in gross income, primarily through licensing income on signing new partnership deals with Axovant Sciences (AXON) and Bioverativ (BIVV). OXB out-licensed its proprietary Parkinson’s gene-therapy to AXON in a $842.5m deal, and the $105m BIVV deal is for haemophilia gene-therapy development.